The Drug Interaction Database (DIDB) provides comprehensive drug-drug interaction (DDI) evidence and tools to support informed decision-making throughout drug development. In this webinar series, we explore the key capabilities of DIDB, including access to in vitro metabolism and transporter data, clinical DDI studies, pharmacogenetic information, organ impairment and food effect data, as well as practical tools for DDI assessment.
Across the webinars, we highlight common challenges researchers face when evaluating drug interaction risk, demonstrate how to efficiently navigate and query DIDB datasets, and showcase how DIDB resources can support real-world applications such as DDI evaluation, clinical trial designing, and concomitant medication selection. These sessions are valuable for both new DIDB users seeking an introduction to the platform and experienced users looking to maximize the depth and efficiency of their DDI assessments.
Explore sessions
Introduction to DIDB: Overview of Key Features, Functionalities, and Resources
Get an introduction to the Drug Interaction Database (DIDB) and learn how its key features, functionalities, and resources support efficient, evidence-based drug-drug interaction (DDI) assessment. Drawing on recent platform enhancements, this session provides an overview of DIDB’s core capabilities, including searching and interpreting DDI data, using integrated tools such as the Concomitant Meds Navigator and DDI Calculator, and accessing the scientific resources available to support clinical development and regulatory decision-making.
Attendees will learn how to:
- Navigate the DIDB platform and understand its core features and organization.
- Locate key DDI data, integrated tools, and supporting scientific resources.
- Identify which DIDB capabilities best support common drug interaction and clinical development workflows.
Presenter: Dr. Ichiko Petrie
日期： 2026 年 9 月 3 日, 星期四
Unlocking DIDB In Vitro Dataset: Metabolism and Transporter Data Overview, Query Functions, and Practical Applications
Learn how to use the DIDB in vitro dataset to explore metabolism and transporter data that support early drug-drug interaction (DDI) assessments. This session demonstrates how to search, customize, and interpret in vitro data to evaluate metabolic pathways, transporter involvement, and mechanistic DDI risk.
Attendees will learn how to:
- Search and filter metabolism and transporter data within the DIDB In Vitro Dataset.
- Interpret in vitro findings to support mechanistic DDI assessments.
- Apply query results to early drug development and DDI evaluation workflows.
Presenters: Dr. Xiaolin Xu, Dr. Arne van Schanke
日期： 2026 年 10 月 7 日, 星期三
Navigating the DIDB In Vivo Dataset: Clinical DDI, Pharmacogenetic, Organ Impairment Effect, and Food Effect Data and Use Cases
Learn how to navigate the DIDB in vivo dataset to efficiently access and interpret clinical drug-drug interaction (DDI), pharmacogenetic, organ impairment, and food effect data. This session provides an overview of the dataset’s organization, search and filtering capabilities, and practical use cases, demonstrating how DIDB’s curated clinical evidence supports DDI evaluations, regulatory decision-making, and drug development.
Attendees will learn how to:
- Search and interpret clinical DDI, pharmacogenetic, organ impairment, and food effect data.
- Evaluate supporting clinical studies and evidence within DIDB.
- Apply in vivo findings to clinical development, protocol planning, and regulatory decision-making.
Presenter: Dr. Ichiko Petrie
日期： 2026 年 11 月 4 日, 星期三
Leveraging DIDB Tools for DDI Assessment and Concomitant Medication Selection: Real-World Use Cases
Learn how to leverage DIDB tools to streamline drug-drug interaction (DDI) assessments and identify appropriate concomitant medications for clinical development. Through real-world use cases, this session demonstrates how tools such as the Concomitant Meds Navigator and DDI Calculator, combined with DIDB’s curated evidence, can support mechanistic evaluations, clinical trial planning, and evidence-based decision-making.
Attendees will learn how to:
- Use DIDB tools to evaluate DDI risk and identify appropriate concomitant medications.
- Build efficient workflows using the Concomitant Meds Navigator and DDI Calculator.
- Apply DIDB insights to support clinical trial design, protocol development, and regulatory decision-making.
Presenters: Dr. Ichiko Petrie and Dr. Arne van Schanke
日期： 2026 年 12 月 2 日, 星期三
Ichiko Petrie, PharmD
Senior Research ScientistIchiko Petrie is a Senior Research Scientist in Drug Interaction Solutions at Certara with more than 10 years of experience in the field of drug interactions, with expertise in pharmacogenetics and clinical drug interactions. She earned her PharmD from the University of Washington. Before joining the Drug Interaction Solutions team, she held roles as a pharmacist and scientific editor across a variety of healthcare and scientific settings.
Xiaolin Xu, PhD
Research ScientistXiaolin Xu is a Research Scientist in Drug Interaction Solutions at Certara. Her work focuses on curating preclinical and clinical drug interaction data for the Drug Interaction Database (DIDB) and performing data analyses to support drug interaction research. She earned her Ph.D. in Pharmaceutics from the University of Washington, where her research investigated the impact of pharmaceutical formulations on the pharmacokinetics and metabolism of combination drug therapies.
Arne van Schanke, PhD
高级总监Arne van Schanke is Senior Director, Early Development, and has been with Certara since 2014. Arne has two decades of experience in the pharmaceutical industry, including roles at MSD, Organon, and for numerous biotech companies via Certara working phases from drug discovery to late-phase development. Arne is a pragmatic biomedical scientist who evolved from biochemical interactions and cancer research into drug metabolism and pharmacokinetics expert and translational modeler working in a broad array of indications including Oncology, Virology, and Fertility, and modalities from small molecules and peptides to antibody drug conjugates and oligonucleotides.
Learn more about DIDB
